Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| TLSA | 6-K | neutral | 4/10 | Tiziana Life Sciences announced that the last patient has completed their last visit in the Phase 2a INFORM-MS trial of | Sep 21, 2026 |
| SCNI | 6-K | neutral | 4/10 | Scinai received Nasdaq confirmation that it has regained compliance with the $1.00 minimum bid price requirement, closin | Sep 21, 2026 |
| AZN | 6-K | bullish | 6/10 | AstraZeneca and Daiichi Sankyo's Enhertu received a positive CHMP opinion recommending EU approval as an adjuvant monoth | Sep 21, 2026 |
| ELOX | EFFECT | neutral | 5/10 | Eloxx Pharmaceuticals' S-1 registration statement (File No. 333-298904) became effective on September 18, 2026, enabling | Sep 21, 2026 |
| DYAI | EFFECT | bearish | 5/10 | Dyadic International's S-1 registration statement (File No. 333-298902) became effective on September 18, 2026, under th | Sep 21, 2026 |
| TLX | PRESS-RELEASE | bullish | 7/10 | Telix announces a transformational merger with ITM Isotope Technologies Munich SE for $1.65B upfront (cash-free/debt-fre | Sep 20, 2026 |
| PRTA | INSIDER-BUY | bullish | 6/10 | 10% owner William P. Scully purchased $843K of Prothena (PRTA) stock on the open market at $8.43/share on September 18, | Sep 20, 2026 |
| CUE | PRESS-RELEASE | bullish | 7/10 | Cue Biopharma announced positive Phase 2 topline results for CUE-221 in chronic spontaneous urticaria (CSU), meeting the | Sep 20, 2026 |
| NTHI | CLUSTER | mixed | 5/10 | Three insiders at NeOnc Technologies traded within a week of a dilutive $15M offering. CEO Amir Heshmatpour made two ope | Sep 18, 2026 |
| ADPT | CLUSTER | bearish | 5/10 | Two ADPT insiders sold a combined $3.05M in open-market sales over a 7-day window. The vast majority ($3.01M) came from | Sep 18, 2026 |
| KRSA | SC 13G | neutral | 4/10 | General Atlantic, L.P. and affiliated entities filed a Schedule 13G disclosing a 6.8% passive stake in Korsana Bioscienc | Sep 18, 2026 |
| SKYE | CLUSTER | bearish | 4/10 | Two 10% owners of Skye Bioscience sold a combined $125K in open-market sales at $1.91/share within a 7-day window. The t | Sep 18, 2026 |
| RVMD | CLUSTER | bearish | 5/10 | Three insiders at Revolution Medicines sold a total of $5.37M in stock over a one-week window, led by a $4.33M sale by a | Sep 18, 2026 |
| LABT | S-1 | bearish | 5/10 | Lakewood-Amedex Biotherapeutics Inc. (LABT) filed an S-1 registration statement to register an additional 4,512,400 shar | Sep 18, 2026 |
| BSEM | S-1 | bearish | 7/10 | BioStem Technologies filed an S-1 registration statement to register up to 12,050,000 shares of common stock for resale | Sep 18, 2026 |
| ADIL | DEFA14A | neutral | 5/10 | Adial Pharmaceuticals filed this DEFA14A to report results from its 2026 Annual Meeting held September 17, 2026. Stockho | Sep 18, 2026 |
| QCLS | 8-K | neutral | 3/10 | Q/C Technologies appointed Yossef Ehrlichman as Chief Technology Officer, promoted from Founding Manager of PIC Developm | Sep 18, 2026 |
| CDT | 8-K | bearish | 7/10 | CDT Equity issued a $2,126,250 senior secured convertible note to J.J. Astor & Co., receiving net proceeds of $1,501,850 | Sep 18, 2026 |
| NEUP | DEFA14A | neutral | 3/10 | Neuphoria Therapeutics Inc. filed a DEFA14A (additional definitive proxy soliciting materials) on September 18, 2026, in | Sep 18, 2026 |
| INM | 8-K | bearish | 6/10 | InMed Pharmaceuticals received a Nasdaq deficiency notice for failing to meet the minimum $2.5M shareholders' equity req | Sep 18, 2026 |
| MBRX | 8-K | bearish | 8/10 | Moleculin Biotech received a Nasdaq Staff Determination Letter on September 15, 2026, stating that its common stock clos | Sep 18, 2026 |
| CNEY | 6-K | bearish | 7/10 | CN Energy Group reported a net loss of $49.5 million for the six months ended March 31, 2026, compared to net income of | Sep 18, 2026 |
| QNRX | S-3 | bearish | 6/10 | Quoin Pharmaceuticals filed an S-3 registration statement to register 9,371,895 ADSs for resale by selling shareholders | Sep 18, 2026 |
| ATOS | 8-K | neutral | 3/10 | Atossa Therapeutics filed an 8-K on September 18, 2026, to make available an updated corporate investor presentation (Ex | Sep 18, 2026 |
| ALEC | SC 13G | neutral | 4/10 | Biotechnology Value Fund L.P. (BVF), a dedicated healthcare hedge fund, filed a new Schedule 13G disclosing a 7.7% benef | Sep 18, 2026 |
| ETRA | 424B4 | bullish | 7/10 | Electra Therapeutics priced its IPO of 23,333,334 shares at $15.00 per share, raising $350.0 million in gross proceeds ( | Sep 18, 2026 |
| KRSA | 144 | neutral | 2/10 | Director Errol B. De Souza filed a Form 144 notice of intent to sell 2,139 shares of Korsana Biosciences common stock, w | Sep 18, 2026 |
| ETRA | 3 | neutral | 3/10 | OrbiMed Advisors and its affiliates filed a Form 3 initial statement of beneficial ownership for Electra Therapeutics, I | Sep 18, 2026 |
| NSRX | 424B5 | bearish | 5/10 | Nasus Pharma filed a prospectus supplement for an at-the-market (ATM) offering of up to $8.5 million of ordinary shares | Sep 18, 2026 |
| UTHR | CLUSTER | neutral | 4/10 | CEO Martine Rothblatt sold ~$7.5M in open-market shares over three days (Sep 14-16), following a $477.6M accelerated sha | Sep 18, 2026 |